Vivos Therapeutics: Nasdaq staff says company complies with equity requirement

What happened

• On Oct 20, 2026, Vivos Therapeutics, Inc. reported that it received a letter from the Listing Qualifications staff of The Nasdaq Stock Market LLC stating that, based on the company’s Current Report on Form 8-K filed Oct 19, 2026, the Staff has determined that the company complies with the minimum stockholders’ equity requirement of Nasdaq Listing Rule 5550(b)(1).
• The filing says the company previously received a deficiency notice in Apr 2026 stating it did not comply with Nasdaq Listing Rules 5550(b)(1), 5550(b)(2), or 5550(b)(3), which require a minimum of $2,500,000 in stockholders’ equity, a minimum $35,000,000 market value of listed securities, or a minimum $500,000 of net income from continuing operations, respectively. The Oct 20, 2026 letter stated that if the company fails to evidence compliance upon the filing of its next periodic report, the company may be subject to delisting and may appeal to a Nasdaq Hearings Panel.

Key details

• Deficiency notice received: Apr 2026, citing possible noncompliance with Nasdaq Listing Rules 5550(b)(1), 5550(b)(2), 5550(b)(3).
• Nasdaq thresholds cited: $2,500,000 stockholders’ equity; $35,000,000 market value of listed securities; $500,000 net income from continuing operations.
• Letter dated Oct 20, 2026, tied the Staff’s determination to the Form 8-K filed Oct 19, 2026.
• Filing includes forward-looking statements and identifies risks including: (i) the risk the company does not evidence compliance upon its next periodic report; (ii) the risk the company’s independent registered public accounting firm or Nasdaq reaches different conclusions about accounting treatment or stockholders’ equity; and (iii) other risks described in the company’s SEC filings.

Why it may matter

• This was reported under Item 8.01 Other events and covers the Nasdaq Listing Qualifications staff’s determination regarding compliance with Nasdaq Listing Rule 5550(b)(1) and the company’s forward-looking statements about continued compliance and related risks. A filing does not show why the insider traded or why the company acted.